Can inhaled nintedanib improve tolerability and adherence in IPF treatment, according to Avalyn Pharma Inc.?
Read More 6 minute read Pharma Industry News What rademikibart Phase 3 data could mean for Connect Biopharma’s immunology strategy (NASDAQ: CNTB) Connect Biopharma’s rademikibart Phase 3 eczema data will debut at AAD 2026. Discover what it means for biologic competition and Connect Biopharma strategy. bySoujanya RaviMarch 13, 2026